The issue of performing tissue sampling from the vesicourethral anastomotic area postradical prostatectomy (transrectal ultrasound-guided biopsy) after radical surgical treatment of local disease has failed, still remains controversial. We review a selection of articles that evaluate this procedure as well as newer diagnostic modalities and we discuss how this technique may have a position in our treatment dilemmas in cases with biochemical failure of undetermined origin.
Introduction
Radical prostatectomy represents a widely accepted treatment for clinically localized prostate cancer diagnosed in healthy men with a high probability for a 10-y life expectancy. 1 Radical prostatectomy remains a main stay of treatment principally because of the high level of confidence that the cancer can be permanently eradicated. 2 Due to careful patient selection and advances in surgical technique, this procedure is quite safe and effective in removing the disease.
Prostate-specific antigen (PSA) remains the most valuable tumour marker for follow-up of patients treated for prostate cancer. Undetectable PSA levels are good indicators of tumour-free status after radical prostatectomy, whereas detectable PSA levels indicate local or distant recurrence. In the absence of measurable clinical symptoms or radiographic evidence of disease, this is referred to as biochemical relapse.
PSA relapse after radical prostatectomy occurs in 16-30% of men by 5 y and in 25-50% by 10 y, and varies significantly between reported series, [3] [4] [5] [6] while after radiotherapy, undetectable PSA levels are only reached in about 35% of the cases. 7 The risk of developing biochemical relapse relates in a statistically significant way, to preoperative PSA, final pathological stage and whole-tumour Gleason score. 3, [8] [9] [10] The differentiation of the potential causes of a rising PSA, has significant therapeutic implications, since if only local recurrence is present, external beam radiation therapy may be helpful, whereas patients with systemic disease would benefit more from hormonal therapy. 11 The average well-informed patient will be quite aware of his PSA value during the follow-up. Most of them are to insist on receiving additional treatment with the onset of a rising PSA. Our first task is to determine the site of recurrence before any administration of further local or systemic treatment therefore, it is important to develop methods to improve our ability to distinguish local recurrence from systemic disease.
PSA relapse following radical prostatectomy can be associated with prolonged survival 12, 13 and in the majority of patients it precedes recurrence of clinical disease. Bone scan and computed tomography are indicated to exclude metastatic or local recurrence that may warrant treatment, even in the absence of symptoms or signs of recurrence.
14 Clinically detectable disease in the absence of detectable PSA is rare, 15 and usually associated with high-grade disease. 16, 17 Symptoms or suspicion of clinical disease should be specifically and irrespectively investigated.
Transrectal ultrasound is an established technique in the evaluation of carcinoma of the prostate. It is useful for guiding biopsies on suspicious lesions, studying a patient with elevated PSA, staging disease before therapy, and helping in designing or performing brachytherapy. Transrectal ultrasound may be of value after radical prostatectomy. 18 Potential uses include sequential scanning of the urethrovesical anastomosis, investigation of a local abnormality found on digital rectal examination or for studying a patient with an elevated PSA level but a palpably normal prostate bed. 18 
Cystourethral anastomosis: sonographic characteristics
Earlier reports 19 have tried to use transrectal ultrasound in the postoperative evaluation of patients following radical prostatectomy. Standard methods like PSA determinations and digital rectal examination (DRE), had their limitations. PSA cannot differentiate local from distant recurrence, while DRE lacks the ability to differentiate normal postoperative changes (ie scar in the anastomotic area) from the presence of actual local recurrence.
Goldenberg et al 18 have studied 30 early postradical prostatectomy patients, within 3 months after the operation. They have reported a series of ultrasound characteristics like anastomotic-bladder neck-ring (100% of the patients) in the transverse plane, and an anterior tissue nodule (40% of the patients) in the sagittal plane. The former represents, as authors have described, the reconstructed bladder neck and the central hypoechoic proximal urethra, while the latter likely represents vesical neck tissue pulled down towards anastomosis, or normal bladder adjacent to an extravesical mass of ligated deep venous complex. Finally, the authors comment that it is important to establish knowledge of the baseline neoanatomy in the prostatic bed postoperativelyythat has variable features, and may be confused with locally recurrent disease (something that is likely with the anterior nodules). So this knowledge could decrease the sampling error, and provide a more accurate yield of true positive and true negative biopsies of the prostatic bed, something that has important implications with respect to possible adjunctive therapy.
In a study by Wasserman et al, 20 25 patients believed to have no tumour on the basis of their level of serum prostate antigen (o0.4 ng/ml), underwent transrectal ultrasound of the vesicourethral anastomosis. Patients' final pathological stage after radical prostatectomy was B (18 pts), C (4 pts) and D1 (3 pts), and TRUS was performed after a median interval of 19.5 months (3-90), while none had palpable abnormalities of the vesicourethral anastomosis (VUA). Findings include a transverse slit-like bladder neck in 12 patients (48%), not identifiable bladder neck (32%), round-shaped (12%) and rectangular-shaped (8%). The soft tissue surrounding the urethra high-pressure zone (UHPZ) was hypoechoic relative to adjacent fat on the axial scan, ovoid, variably marginated and predominantly anterior to the UHPZ. No perianastomotic tissue could be identified in five patients (20%). On the longitudinal plane, this tissue was more difficult to distinguish from surrounding fat and the anterior bladder wall. It appeared to indent the anterior bladder wall in 20 patients (80%). Of the 20 patients in whom this tissue was visible, it was isoechoic relative to the bladder wall in 16 patients (80%), hypoechoic in three patients (15%) and hyperechoic in one patient (5%). The profile of the VUA in the midsagittal plane was smoothly tapered in 13 patients (52%) and blunt, patulus or both in 12 patients (48%). The authors suggest that the TRUS findings described in their paper may prove useful in a routine TRUS examination performed 3-6 months after surgery, and knowledge of a patients' baseline anatomy, may enable a better estimate of later deviation from normal and may improve accuracy of TRUS-guided biopsy sampling. The addition of colour Doppler imaging (CDI) during transrectal ultrasonography was tested by Sudakoff et al. 21 Although the authors acknowledge the fact that this study reports on small number of patients and is of limited follow-up, they concluded that CDI during transrectal sonography improves the detection of early recurrent or residual prostatic cancer compared with transrectal sonography alone. Abnormal vascularity was present in 12 of 14 biopsy-proven tumour recurrence, although it was not possible to determine if the vascularity detected with CDI was produced by the normal glandular elements, tumour or combination of both. Their study showed that CDI during transrectal sonography could improve the detection of recurrent tumour. In all, 48% of the patients had abnormal greyscale sites and 43% of the grey-scale abnormalities proved as a recurrent tumour (10 pts), while 12 patients (53%) had CDI-detected hypervascular areas, that corresponded to grey-scale abnormalities that were positive for tumour recurrence in 10 of 12 patients.
In terms of suspected local recurrence (ie PSA raise, negative CT-scan and bone scan), Wasserman et al 22 also have studied the anatomic appearance of postoperative vesicourethral anastomosis. In a total of 16 patients with a rising PSA level above 0.4 ng/ml, the authors concluded that the appearance on TRUS scans in those patients compared to patients without suspected recurrence, had no significant difference. All patients in their study showed a slightly larger mean volume of perianastomotic tissue compared to that in a previous group without rising PSA. The authors also comment that they agree to a previous comment by Resnick 23 that 'the presence of recurrent prostatic carcinoma without an abnormal PSA level and/or DRE would be unusual and, therefore, the use of transrectal ultrasonography in patients without abnormal findings would probably be unrewarding'.
In a similar early study by Salomon et al, 24 in a group of 21 patients, sonographic detection of a mass at the vesicourethral anastomosis or in the perianastomotic region had a strong correlation with obtaining positive perianastomotic biopsy results. This observation agrees with that of Foster et al. 25 They also comment that the thickness of the anterior and posterior anastomotic soft tissues and the contour of the anterior bladder neck were not important factors in predicting biopsy results, in agreement to previous studies. 18, 20 In their study, all perianastomotic masses were less echogenic than the surrounding retroanastomotic tissue and approximately isoechoic compared with the vesicourethral anastomosis and bladder neck.
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So there are various findings in regard to the appearance of the perianastomotic area, that seem to vary from 'normal', lobular, asymmetric or with nodules (masses). In cases without a PSA raise, the surrounding tissue can be isoechoic, hyperechoic or slightly hypoechoic in relation to fat, or even absent. Discrete masses are commonly described in cases with biochemical failure. 18, 20, 21, 24 Also, lack of integrity of the echogenic retroanastomotic plane may be a secondary indicator of local recurrence, since this finding correlated well with histology detection of perianastomotic tumour, 24 but there were no specific attempts to sample correlation with TRUS-detected masses. The nonspecificity of the changes in the perianastomotic region is a not suprising phenomenon especially if fibrotic postoperation tissue is accounted for this appearance, irrelevantly of the possibility of local recurrence (Figures 1-3 ).
Anastomotic TRUS-guided biopsy Predicting factors
Factors that predict progression after radical prostatectomy include high preoperative PSA, high tumour grade, extracapsular extension, seminal vesicle invasion, positive margins, metastasis to the lymph nodes and large tumour volume. 26 Positive surgical margins result from incising inadvertently into the prostate or incising into extraprostatic tumour that extends beyond the limits of resection. 27, 28 During surgery for prostate cancer, excising broad margins around the neoplasm may be difficult because the anatomy of the prostate fossa often limits surgical margins within millimetres of the prostatic capsule. [29] [30] [31] Since these adverse pathological factors are often detected concurrently, individual effect on progression is difficult to assess.
Cancer in patients with positive margins is more likely to progress biochemically, locally and systemically. 26 Shekarriz et al 11 have studied the predictive value of several variables (including pretreatment PSA value, DRE at the time of biopsy and original/pathological stage) in 45 patients with a rising PSA after radical prostatectomy and negative bone scan. The authors have reported that 24 patients (53%) had a positive biopsy for cancer taken from the anastomotic area after radical prostatectomy. Among the variables tested for their impact on the biopsy outcome, multivariate analysis has shown that PSA greater than 1 ng/ml and extraprostatic extension of the disease in specimen were statistically important parameters in predicting a positive biopsy from vesicourethral anastomosis. Although there was no detailed margin classification and no report of benign tissue as a finding in these biopsies, they also do not comment on the TRUS findings in relation to a positive biopsy.
In a similar report by Connolly et al, 32 114 patients with an elevated PSA, and a negative bone scan, were examined by TRUS and TRUS-guided biopsy. The authors have also reported a similar rate of positive biopsy (54%) but nearly one-third of patients required more than one TRUS biopsy sessions to establish local recurrence. Radical prostatectomy specimens were also reviewed in respect to local recurrence, and the authors concluded that the status of the resection margins did not differ significantly between the two groups (ie with or without local recurrence). 
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Hypoechoic lesions were the commonest finding in TRUS in both studies, 11, 32 while cancer detection rates in groups with a hypoechoic lesion, were 64 and 66%, respectively. In this latter study, 32 the authors conclude that TRUS had a higher sensitivity than DRE, but a lower specificity. No difference in establishing local recurrence existed in respect of surgical margins status, although more patients with seminal vesicle involvement (36 vs 23%) and less patients with positive lymph nodes (8 vs 20%) had local recurrence. They also report that serum PSA levels were significantly higher in cases with local recurrence (median 5,7 vs 2,7 ng/ml) but no relationship was found, between serum PSA levels and volume of local recurrence, in cases without neoadjuvant or adjuvant manipulations. Although they imply that they have included patients with a previous history of pelvic irradiation or androgen deprivation before the operation in this study, the authors conclude with certainty that local recurrence is characterized as a hypoechoic mass or tissue thickening and is most likely to present at the level of the anastomosis.
Saleem et al 33 found also an initial positive biopsy rate of 38%, and including repeat biopsies the detection rate was 55%. In all previous studies, neither low serum PSA nor normal DRE ruled out the possibility of a positive biopsy of the anastomosis. Also, the interval between surgery and the time of anastomotic TRUS biopsy (or biochemical failure) was longer in patients with a positive biopsy that in patients with negative biopsy. 33 This remark agrees also with reports from Fowler et al 34 and Partin et al, 35 while Lightner et al 36 have reported differently. Nevertheless, this fact does not rule out the possibility of a positive biopsy in cases with earlier occurrence of biochemical failure, so it is not advisable to avoid anastomotic biopsy due to that fact. In terms of specimen pathology and how it correlates to local recurrence or a positive anastomotic biopsy, Van den Ouden et al 37 reported that overall progression and local recurrence were significantly different for the positive and negative margin groups, and this significance persisted through different pT categories. But also, distant progression rate was significantly different between positive and negative margin groups, although this difference did not persisted along pT stage categories.
Foster et al 25 have found that local recurrence was not only confined to stage C disease but also to stage B disease. They also have not found any correlation between grade of recurrence and radical prostatectomy Gleason score, or PSA values before radical prostatectomy.
Diagnostic accuracy: histological outcome
As early as 1990, Lightner et al 36 evaluated the location of recurrent disease in 63 patients with carcinoma of the prostate who had abnormal levels of PSA (40.4 ng/ml). Among 57 patients without evidence of disease by the standard imaging techniques or DRE, needle biopsies of the anastomosis revealed local disease in 42%. No local disease was found in 30 postradical prostatectomy cases with normal PSA levels that were also evaluated. So, they concluded that PSA but not DRE is an excellent early indicator of possible local disease, since they have found that many of the patients had local recurrence in the urethrovesical anastomotic area despite apparently unremarkable rectal examinations. Of note is that in most cases, the surgeon performed a circumferential tissue sampling from both bladder neck and urethral anastomotic end, and this tissue was also analysed. The anastomosis was to be completed if only clear margins were achieved or (rarely) when the surgeon believed that further tissue removal to achieve tumour-free anastomotic ends would compromise continence. Moreover, at least some of the patients in this study had received adjuvant radiation therapy, and needle biopsy of the urethrovesical anastomotic area was conducted without the use of transrectal ultrasound. Thus, a 42% ratio of positive random biopsies from the anastomotic area seems quite impressive.
The use of transrectal ultrasound in the evaluation of local recurrence, after radical prostatectomy, came soon after, in an attempt to improve the diagnostic value of biopsy taken from vesicourethral anastomosis.
Parra et al 19 introduced the use of TRUS in the evaluation of pelvic malignancies, following a radical operation. Their report studies cases after radical prostatectomy as well as radical cystectomy. Being an early study, it reports some quite remarkable detection of local recurrence, even with old types of TRUS equipment. This study lacks the careful patient selection and discipline examination (only 11 patients underwent TRUS-guided biopsy in a total of 20 patients in two different types of malignancy, and mostly with a palpable mass in DRE), yet it can be regarded as a pioneer incorporation of TRUS in evaluation of pelvic malignancies' local recurrence. Another early report comes from Abi-Aad et al, 38 who identify a 45% of a total of 20 patients as having local recurrence with an elevated PSA level (40.4 ng/ml) postradical prostatectomy. They also report a significant correlation between abnormal TRUS findings and histological confinement of recurrent malignancy (77%) whereas DRE had a lower correlation rate (44%), although they admit that cancer can be found even in lack of abnormal DRE or TRUS findings. They also admit that a negative initial biopsy does not rule out the presence of malignancy in the anastomotic area, since miss of local recurrence area during biopsy taking may occur due to small volume and/or lack of specific anatomic characteristics of the malignant tissue. They also suspect that in cases with negative metastatic or transrectal outcome but stable PSA levels (an overall of 20% of their cohort of patients), residual prostate tissue-possibly benign-may be considered responsible for that fact. Some similar results are also reported by Kapoor et al. 39 Leventis et al, 40 in their study from 99 patients, reported 41% of local recurrence, with the interesting correlation between findings and positive biopsy rates. By so, they have reported as follows: anastomotic area 56 and 61%, bladder neck 26 and 54%, retrovesical space 26 and 54% and more than a site 14 and 71%, respectively. Also an increased biopsy rate with increasing PSA levels was noted. These findings should be regarded under the author's comment that all patients had a palpable abnormality at the time of the evaluation, a sustained elevation in the serum PSA or both. This is somewhat interesting especially if we note that none of these patients had received any form of adjuvant treatment Postradical prostatectomy TRUS-guided anastomotic biopsy T Anagnostou et al (radiation or hormonal treatment). Although the initial biopsy rate was lower than previously reported (30%), it is interesting that nearly half of these patients had 'normal' findings in the transrectal ultrasound, but still 20% of them had a positive biopsy for adenocarcinoma of the prostate. In cases with abnormal TRUS findings (51%), 62% had a positive biopsy for recurrent malignancy. DRE's accuracy was different in that aspect (finding of recurrent tumour in 30% of cases with normal DRE, but in 78% of cases with abnormal DRE). In terms of histological outcome, several studies report a variety of histological findings, while the previous mentioned studies 11, 19, 32, 33, [36] [37] [38] [39] [40] have identified recurrent adenocarcinoma of the prostate as the only evidence of local presence of prostate tissue (Table 1) .
Foster et al 25 have evaluated 43 patients with persistently detectable PSA levels, and mean duration after radical prostatectomy 44.8 months. They reported that out of eight patients whose initial biopsy revealed normal prostate tissue or BPH, repeat biopsy was undertaken in six and it showed cancer in four of them (66%).
Fowler et al 34 have studied a series of 41 men and having obtained 61 biopsy results from these patients, they confirmed a 39% initial biopsy positive rate for adenocarcinoma of the prostate with an overall rate of 59%. Interestingly, they report six cases where only benign prostate tissue was recovered from biopsy specimens. Ripple et al 41 have reported on the anastomotic biopsy pathology of a series (no. 37) of locally recurrent cases proved by transrectal ultrasound biopsy, and came with the interesting finding of coexisting benign prostatic acini in 14% of these biopsies.
Newer imaging techniques
Newer techniques that have also emerged for the evaluation of vesicourethral anastomotic area include colour Doppler transrectal US (CDI), CT, MRI, radioactively labelled monoclonal antibody scanning and positron emission tomography (PET). Colour Doppler has been used for the detection of local recurrence. 21, 42 Remzi et al 42 have reported on the value of colour Doppler in a study where every patient had a TRUSbiopsy from the anastomotic region. Colour Doppler images were categorized as normal, abnormal and negative (0-1 on a colour scale). From that they have counted true positive (A), false negative (B), false positive (C) and true negative cases (D), finding sensitivity (A/A þ B) and specificity (D/C þ D) of 84.6 and 92.4%, respectively. Finally, they concluded that CDI was the most powerful predictor of local recurrence as compared to time to recurrence and PSA density.
CT is not sufficiently sensitive in recognizing local disease recurrence following radical prostatectomy for prostatic carcinoma, 43 although it still plays a part in the planning of radiation treatment in confirmed local recurrence. 43 Preliminary data show that PET may be more sensitive than CT for the detection of lymph node metastasis, but bladder activity poses a serious problem in the identification of local prostate cancer recurrence. 44 MR imaging evaluation either with a transrectal surface coil 45 or a body coil, 46 is a useful imaging tool to study the anatomy of vesicourethral anastomosis in men after radical prostatectomy, suspected of local recurrence (Figure 4) . The costs and the lack of obtaining biopsy proof of local cancer by MRI techniques is a major difference to transrectal ultrasound.
Indium 111 ( 111 In) capromab pendetide, which is a radiolabeled monoclonal antibody, has been used in the evaluation of patients in whom primary treatment of prostate cancer fails. Kahn et al 47 have assessed the ability of I 131 indium-capromab pendetide (immunoscintigraphy) to differentiate between local and distant recurrence in a multi-institutional study in patients with biochemical recurrence after radical prostatectomy, median PSA level 2.6 ng/ml at biochemical failure and median time from prostatectomy to immunoscintigraphy 24.7 months. They reported 49% sensitivity and 71% specificity value while positive predictive value was 50% and negative predictive value was 70%. 
Conclusions
The clinical usefulness of serum PSA is greatest when monitoring disease status or response to definite therapy for prostate cancer. 15 Men with isolated elevation of serum PSA after radical prostatectomy have a 25% likelihood of harbouring an occult local recurrence while the actuarial likelihood of an elevated serum PSA increased with increasing clinical stage, Gleason score, preoperative serum PSA concentration and pathologic stage. 15 The idea of positive surgical margins, as a result of unintentional disruption of the prostatic capsule may explain the detectable postoperative PSA. Several authors have reported about the incidence of bladder neck or apical soft-tissue margins in relation to surgical technique of radical prostatectomy. [48] [49] [50] [51] [52] Djavan et al 53 were among the first to report the need of redefining PSA nadir after radical prostatectomy due to the finding of benign positive surgical margins after radical prostatectomy.
The interval between surgery and the time of evaluation with TRUS and biopsy is significantly longer in patients with a positive biopsy, but this fact should not discourage the decision on performing TRUS evaluation of the vesicourethral anastomosis in earlier cases of biochemical failure.
Transrectal ultrasound-guided biopsy after radical prostatectomy is a safe procedure. Main possible complication is bleeding from the anastomotic site or haematuria but occurs rarely. 25, 36, 38 Transrectal ultrasonography enhances the detection of biopsy-positive disease if compared to DRE alone, in cases with biochemical recurrence after radical prostatectomy where there is no evidence of distal disease.
If TRUS is combined to DRE it proves better detection rates of local recurrence. Although further experience or technology may enable us to establish specific findings for local recurrence, a limitation of transrectal ultrasonography today, is the lack of specificity of when hypoechoic abnormalities are detected in the vesicourethral anastomotic area.
Repeat biopsy may be the answer for this disadvantage although the scheme or timing of repeat biopsies in these cases has not been yet agreed on (Table 2) . If initial Postradical prostatectomy TRUS-guided anastomotic biopsy T Anagnostou et al biopsy fails to establish local recurrence, one repeat biopsy would successfully diagnose local cancer in another 16-17% of cases. 25, 34 Some authors 36 have also evaluated cases with normal PSA levels (o0.3 ng/ml) or lower 33 than 0.5 ng/ml, and reported that no local disease was discovered. These findings support the hypothesis that presence of local recurrence in PSA range below 0.5 ng/ml seems unlikely.
Radiotherapy and androgen deprivation are the most common forms of secondary treatment in prostate cancer recurrence after local treatment has failed. A positive anastomotic biopsy did not predict an improved outcome after radiotherapy following radical prostatectomy, 54 while little data exist in the literature to support the theory that patients with biopsy proved local recurrence respond significantly better to salvage radiotherapy than those with PSA recurrence or a negative biopsy.
The fundamental problem relating to recommending TRUS biopsy of the anastomotic area as standard procedure is that the biopsy outcome alone does not reliably rule out either local (if biopsy negative) or systemic disease (if biopsy is either positive or negative) that may not be detected with the current imaging modalities.
Large prospective studies will be needed to establish the true specificity and sensitivity of the procedure, while to date there still exist different therapeutic approaches to this setting by urology surgeons. 36 Fowler et al 34 
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